Drugging the undruggable
by targeting RNA
Targeting RNA: a solution to undruggable targets
RNA is involved in every facet of cell biology — from coding for important therapeutic targets, to regulating splicing and serving as a molecular scaffold. Because up to 85% of cellular proteins may be undruggable with small molecules, targeting the RNA of disease-causing genes can be an effective approach to eliminate proteins before they’re even made.
Wayfinder Biosciences is building a pipeline of small molecule assets for undruggable targets in oncology and neurodegeneration.
Our Technology
Our platform combines proprietary experimental and AI/ML virtual screening technologies to rapidly screen for small molecule modulators of RNA structure and function. Our technology is centered around Wayfinder’s RNA sensors, which are biophysically designed to generate a quantitative signal only when a small molecule modulates the structure of the target RNA.
Partner with Wayfinder
RNA targeting small molecules is a new modality. With our data-driven approach, we are learning generalizable rules to design functional molecules that not only bind, but also effectively modulate RNA structure and function.
External drug discovery
We are seeking pharma and biotech partners interested in developing RNA-targeting small molecule therapies for new or existing targets by leveraging quantitative datasets and AI/ML insights enabled by Wayfinder.
In-house drug discovery
We are leveraging our platform to develop new small molecule modulators for undisclosed disease-related RNA targets in oncology and neurodegeneration.
Areas of interest: oncology, neurodegeneration, infectious and rare diseases